December 21, 2021 07:21 AM ESTUpdated 09:02 AM
FDA+

FDA clears first long-act­ing HIV-pre­ven­tion in­jectable, giv­ing Vi­iV claim to his­toric OK

Josh Sullivan

A long-act­ing in­jectable treat­ment for the pre­ven­tion of HIV has been giv­en the go-ahead by the FDA for use in adults and chil­dren weigh­ing at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Pfiz­er, GSK add risk of Guil­lain-Bar­ré to RSV vac­cine la­bels at FDA's re­quest

A service from the Financial Times